WeVote
Log In

Bill

Bill

S 4208

Prohibits pharmacy benefit manager from using spread pricing as model of prescription drug pricing; requires transparency in provision of pharmacy benefits management services.

2026-2027 Regular Session Introduced by Raj Mukherji

Prohibits spread pricing by PBMs and requires transparent disclosures of true drug costs, rebates, and services to improve pricing clarity for plans and consumers.

0
WeVote Research Nonpartisan
Bill Summary · S 4208

Summary: S 4208 (New Jersey, Session 222)

Title

Prohibits pharmacy benefit manager from using spread pricing as model of prescription drug pricing; requires transparency in provision of pharmacy benefits management services.

Purpose and Intent

  • To reform how pharmacy benefit managers (PBMs) price and disclose the costs and services associated with prescription drug benefits.
  • To eliminate the use of spread pricing as a pricing model within the PBM framework and to increase transparency in PBM operations and compensation.
  • Aims to reduce hidden costs passed to employers, health plans, and patients, and to improve accountability and consumer protection within the prescription drug supply chain.

Key Provisions and Changes

  1. Prohibition on Spread Pricing

    • The bill prohibits PBMs from using spread pricing as their method of pricing prescription drugs and related services.
    • Spread pricing typically involves the PBM retaining a portion of the difference between what the payer (e.g., a health plan or employer) pays for a drug and what the pharmacy is reimbursed, potentially masking true costs. This bill seeks to terminate that practice in favor of transparent pricing structures.

  2. Transparency Requirements

    • PBMs must provide clear, detailed disclosures regarding:
      • The actual costs of prescription drugs to payers and patients.
      • All compensation received by the PBM from manufacturers, pharmacies, or other entities in connection with the provision of PBM services.
      • The specific services provided by the PBM (e.g., formulary management, rebate arrangements, claim processing, patient support) and the corresponding fees or revenue streams.
    • Mandates standardized reporting formats to enhance comparability across plans and PBMs.

  3. Reporting and Record-Keepings

    • PBMs must maintain and provide access to records substantiating pricing, rebates, discounts, and other remunerative arrangements.
    • Requirements may include periodic reporting to a state health or insurance department or a designated regulatory body.

  4. ** consumer and Plan Impact Protections**

    • Measures intended to reduce hidden costs to consumers through more transparent pricing.
    • Potential impact on formulary design and rebate strategies, with a requirement to align incentives toward patient access and affordability.

  5. Enforcement and Penalties

    • Provisions outlining enforcement mechanisms for noncompliance, which may include penalties, corrective action orders, or other regulatory remedies.
    • Possible whitelisting or certification processes for PBMs operating within the state.

  6. Effective Date and Timeline

    • The bill would specify an effective date for the prohibitions and transparency requirements, with phased implementation or a clear launch date.
    • Transitional provisions may address existing contracts and ongoing PBM arrangements.

Affected Parties

  • Primary Affected Entities
    • Pharmacy Benefit Managers operating within New Jersey.
  • Secondary Affected Parties
    • Employers, health plans, and self-insured groups that contract with PBMs.
    • Pharmacies and drug manufacturers through transparency in rebates and pricing arrangements.
    • Consumers/patients receiving prescription drug coverage through plans using PBMs.

Procedural and Timeline Considerations

  • The bill outlines reporting, record-keeping, and disclosure timelines to ensure timely compliance.
  • It may establish a regulatory oversight mechanism (e.g., a state department or bureau) to administer, monitor, and enforce the provisions.
  • There could be a transition period to allow PBMs to adjust pricing systems, contracts, and data-sharing capabilities.

Potential Impacts

  • Pricing Transparency: Expected to enhance visibility into drug pricing and PBM revenue streams, enabling plan sponsors and consumers to understand true costs.
  • Market Dynamics: Prohibition of spread pricing could alter PBM revenue models and rebate strategies, potentially affecting rebates to plans and member cost-sharing structures.
  • Administrative Burden: Increased reporting and record-keeping obligations may raise compliance costs for PBMs but improve regulatory oversight.
  • Patient Access and Affordability: By curbing opaque pricing, the bill aims to support more predictable out-of-pocket costs and informed decision-making.

If you’d like, I can tailor this summary to a specific audience (e.g., policymakers, insurers, patient advocates) or add a comparison to current NJ PBM practices and related federal guidance.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.